And the winner is …. Dr. Hein Coolen

Published on 2018-09-14

Written by Paul Janssen Futurelab

Dr. Hein Coolen of Fair Medicine is the winner of the Paul Janssen Futurelab Nomination Letter 2018 for the best clinical protocol entitled ‘A phase 2 Trial of monobenzone-imiquimod (MI) therapy in combination with nivolumab for the treatment of unresectable, Stage IIIB to IVM1c Melanoma’.

Dr. Coolen developed the clinical trial protocol together with a mentor during the blended course Clinical Development of Paul Janssen Futurelab. With his proposal he won the Best Clinical Trial Protocol Challenge 2018 and the Paul Janssen Futurelab Nomination Letter. Dr. Coolen developed the protocol in collaboration with researchers and clinical-investigators in the Amsterdam UMC (AMC and VUmc) and NKI/AVL. With this nomination they can now apply for the € 500,000 ZonMw grant, which will allow them to execute the clinical trial in the Netherlands.
Hein Coolen and colleagues, the winners of the Paul Janssen Futurelab Nomination Letter 2018. From left to right: prof. dr. Rosalie Luiten (Amsterdam UMC), dr. Germaine Relyveld (NKI/AVL), Dr. Hein Coolen (Fair Medicine), Dr. Alexander van Akkooi (NKI/AVL), Dr. Marcel Bekkenk (Amsterdam, UMC). Photo by Flora Madu.
The next edition of the blended course Clinical Development starts September 24th 2018; the corresponding on-campus part is in June 2019.